XtalPi (HKG:2228) recorded an attributable profit of 123.7 million yuan in the year 2025, compared with an attributable loss of 1.52 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.
Earnings per share stood at 0.03 yuan for the period, compared with a loss per share of 0.79 yuan in the previous fiscal year.
The pharmaceutical research firm's revenue surged 201% to 802.6 million yuan from 266.4 million yuan previously.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.